Clinical Trial Update: Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients

View source ↗

Summary

A completed retrospective study evaluated MRI with MULTIHANCE at 0.10 and 0.05 mmol/kg in patients with central nervous system diseases, including CNS neoplasms…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous Neoplasms
• Central Nervous System Diseases

Drugs mentioned

• MULTIHANCE (Gadobenate dimeglumine)

Snippet

Sponsor: Bracco Diagnostics, Inc | Conditions: Central Nervous System Diseases, Central Nervous System Neoplasms | Status: COMPLETED